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"Medical care was making little difference anyway. Mary Tullidge daughter of Dr. 
George Tullidge, died twenty-four hours after her first symptoms. Alice Wolowitz, a 
student nurse at Mount Sinai Hospital, began her shift in the morning, felt sick, and was 
dead twelve hours later." 
"In ten days - ten days! - the epidemic had exploded from a few hundred civilian cases 
and one or two deaths a day to hundreds of thousands ill and hundreds of deaths each 
day." 
Excerpts from Chapter Nineteen, "The Great Influenza" by John. M. Barry. 
It is impossible to predict with absolute certainty whether we will ever face another 
pandemic like that of the 1918 Spanish flu. But nevertheless, we must be prepared to 
fight it in the event that it might happen. Increasing our knowledge of the molecular 
biology of the virus is by far the best way to get ready for it. In fact, it might be the only 
way.   
GRA. 
1. Introduction 
1.1. A coated agent with a fragmented genome: The infectious viral particle of 
Influenza A Virus 
Influenza A virus (IAV), a member of the Orthomyxoviridae [1], is an enveloped, negative-
sense, RNA virus that contains a segmented genome composed of eight different viral RNA 
strands (vRNAs), each coding for one or two different viral proteins [2]. The viral particle is 
composed of a phospholipid bilayer membrane derived from the plasma membrane of the 
host, decorated by two single transmembrane domain viral proteins, the hemagglutinin 
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(HA) and neuraminidase (NA) proteins, and one pore-forming protein, the matrix 2 (M2) 
ion channel protein [3]. The viral envelope surrounds a relatively irregular viral 
nucleocapsid formed by the viral matrix (M1) protein, which in turn surrounds eight viral 
ribonucleoproteins (vRNPs) that appear to be placed in a well organized cylindrical 
arrangement [4]. Each vRNP is made of a single stranded viral genomic RNA segment 
covered by numerous copies of the viral nucleoprotein (NP), and a single copy of the viral 
RNA-dependent RNA-polymerase (RdRp), which is associated to a double stranded RNA 
structure formed by 12 and 13 complementary nucleotides at the 5' and 3' end regions in 
each gene segment, respectively. The viral RdRp is a trimeric complex made of single copies 
of the basic one, basic two, and acid RNA polymerase proteins (referred to as PB1, PB2, and 
PA, respectively). Also associated to the infectious viral particle is the nuclear export protein 
(NEP), formerly known as non-structural protein 2 (NS2), a protein involved in the export of 
vRNPs from the nucleus of infected cells (Reviewed by Nayak et al [5], and Rossman and 
Lamb [3]) (Figure 1). Finally, recent analyses have demonstrated the incorporation of several 
host-cell encoded proteins into the mature viral particle [6].  
 
Figure 1.  
1.2. A nuclear RNA virus: The life cycle of influenza A Virus 
The infectious cycle of the virus starts with the binding of the infectious viral particle to the 
plasma membrane of the host cell. This initial binding is mediated by the viral HA protein, 
which exhibits high binding affinity for sialic acid molecules coating the extracellular 
domains of integral membrane proteins located at the plasma membrane. Upon binding, the 
virion enters the cell by receptor mediated endocytosis. Acidification of the resulting 
endocytic vesicle triggers the release of the vRNPs from the viral nucleocapsid and the 
fusion of the viral envelope with the endocytic membrane, thus allowing the discharge of 
the vRNPs into the cytoplasm of the infected cell [1]. Then,  in a process mediated by cellular 
karyopherins, the vRNPs move rapidly into the nucleus (reviewed by Boulo et al. [7]). This 
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nuclear translocation is a very peculiar and intriguing property of influenza virus, which 
makes it quite unique among RNA viruses, as most RNA viruses remain in the cytoplasm, 
where they carry out most of their functions, including viral replication. However, influenza 
virus requires access to the cell nucleus for successful transcription and replication of the 
viral genome. Once in the nucleus, the incoming RdRp associated to the vRNPs initiates 
synthesis of viral mRNA and produces the first round of viral protein synthesis, which leads to 
the expression of the early viral proteins PB1, PB2, PA, NP, and non-structural protein 1 (NS1) 
[1]. NS1, plays a critical role during infection by neutralizing cellular antiviral responses and 
increasing viral protein synthesis, while decreasing the synthesis of cellular proteins (reviewed 
by Hale et al. [8], Lin et al. [9], and Krug et al. [10]). The role of neutralizing antiviral defenses 
has been recently shown to be shared by another viral protein produced by a limited number 
of viral strains: The so-called PB1-F2 protein, a 90 amino acid protein produced by an 
alternative ORF contained within the PB1 gene segment [11-12].  
Newly synthesized RdRps drive the synthesis of mRNA coding for late viral proteins, 
including HA, NA, M1, NS2, and M2, and later on undergo a shift in activity, from 
transcription to viral replication. Upon synthesis of new vRNA, the newly synthesized 
vRNA gene segments are incorporated into vRNPs that are exported out of the nucleus 
thanks to complex interactions established with the viral proteins NEP and M1, and the 
cellular karyopherin CRM1 [13]. The vRNPs are then incorporated into new viral particles 
by a budding process that takes place at lipid rafts located at the apical surface of the plasma 
membrane, in an area referred to as the budozone (reviewed by Vait and Thaa [14]). These 
lipid rafts contain the viral integral membrane proteins HA, NA, and M2, and the 
interactions established between the cytosolic tails of these proteins, particularly HA and 
NA, the viral structural protein M1, and vRNPs, appear to play a critical role as drivers of 
the budding process (reviewed by Nayak et al. [5], and Rossman and Lamb [3]). The 
budding process is completed by membrane scission, a process that involves the activity of 
M2 [15], and the infectious viral particles are released into the extracellular environment 
thanks to the activity of NA, which cleaves sialic acid molecules off the cell surface, 
therefore freeing the virus from interacting with its cellular receptor [3].   
1.3. How influenza affects humans: Clinical effects of influenza in the human 
host 
Seasonal epidemic influenza usually causes an acute but self-limited infection of the 
respiratory tract, characterized by acute febrile symptoms, sudden onset of sore throat, 
nonproductive cough, rhinorrhea, myalgia, headache, and general malaise. Uncomplicated 
influenza usually resolves within 3 to 7 days of the first appearance of symptoms, although 
the cough and the general malaise may persist for up to a couple of weeks [16]. Complicated 
influenza is usually associated to the presence of other pre-existing medical conditions in 
the infected person, including pulmonary or cardiac disease, diabetes, obesity, and 
hypertension. Complicated influenza may result in primary influenza viral pneumonia, lead 
to secondary bacterial pneumonia, or exacerbate other underlying medical conditions, most 
frequently of pulmonary or cardiac nature. Most of the complicated cases of influenza occur 
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among people 65 years old and over. In the United States alone, seasonal epidemic influenza 
is estimated to be responsible for approximately 200,000 hospitalizations and 34,000 deaths 
every year [17-18]. Influenza has been shown to have strong pro-thrombotic and pro-
inflammatory effects in the host. Therefore, a significant number of deaths associated with 
seasonal influenza infection are likely to be a consequence of cardiovascular events 
facilitated by pre-existing cardiovascular disease but triggered by influenza infection [19].  
In contrast with the relative mildness of seasonal epidemic influenza, pandemic influenza 
usually has a more aggressive presentation. Pandemic influenza is associated with the 
introduction into the human host of a virus exhibiting an avian-type HA gene segment 
showing limited similarity to pre-existing human influenza viruses [20]. This determines 
that most humans will have few or no pre-existing cross-reactive antibodies against the 
avian-type HA protein that coats the viral particle, thus allowing unobstructed viral 
multiplication in the human host during the initial hours after infection. The fast viral 
growth that ensues under such conditions leads to a more aggressive disease presentation, 
accompanied sometimes by an unregulated cytokine production, a situation referred to as a 
"cytokine storm", that leads to an exaggerated pro-inflammatory response in the lungs [21]. 
Lung inflammation may in turn result in rapid progression to viral pneumonia, and in some 
cases to acute respiratory distress syndrome (ARDS), a condition that requires mechanical 
ventilation and may lead to death [20].  
1.4. Our anti-influenza arsenal: Current therapeutic and prophylactic options 
against influenza 
Currently, our most effective weapon against influenza virus is vaccination. However, 
effective vaccination requires a close antigenic match between the prevailing viral type 
being transmitted throughout the population and the viral strain used for vaccine 
development. The high mutational rate associated to the error prone viral RdRp, introduces 
frequent changes in the antigenic makeup of the virus. This imposes the need for an annual 
vaccination aimed at stimulating the immune system with a vaccine virus that closely 
resembles the changes occurring in the prevalent viral population. Selection of the viral 
strain to be used and vaccine production itself are both time consuming processes, and 
vaccine production against a novel pandemic virus may easily take 3 to 6 months, therefore 
keeping vaccination from playing an important role in the prevention of the first wave of 
viral infections during a pandemic, as recently evidenced during the 2009 H1N1 "swine" flu 
pandemic [22]. Further complicating the rapid production of anti-pandemic influenza 
vaccines is the potential undesired selection of viral variants that grow well in embryonated 
eggs, the current preferred media for amplification of the viral particles used for vaccine 
production. This may lead to the unintended selection of viral strains that are mismatched 
with the circulating viral strain [23].  
A truly promising development related to influenza vaccines is the possibility of developing 
"universal" vaccines capable of  triggering the production of broad-spectrum neutralizing 
antibodies effective against most (if not all) influenza strains. In addition to M2 and NP, the 
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targets classically pursued for the development of universal influenza vaccines [24],  it has 
been recently demonstrated the existence of two regions within the viral HA molecule that 
are capable of triggering broadly neutralizing antibodies: The stem and the receptor-binding 
pocket. Animal models have shown substantial progress in the ability to enhance the 
production of antibodies against the stem region, which is normally ignored by our immune 
system due to its inaccessibility [25]. However, it is still uncertain whether the success 
observed so far in animal models will be achievable in humans.  
Antiviral drugs constitute our second most valuable weapon against influenza virus. 
Currently, there are two main types of FDA-approved anti-influenza drugs: Those targeting 
the viral M2 proton ion channel, which are chemically derived from Adamantane and 
therefore referred to as Adamantanes; and those targeting the viral neuraminidase protein, 
referred to as neuraminidase inhibitors. There are two M2 ion channel inhibitors: 
Amantadine (Symmetrel®) and Rimantadine (Flumadine®). These drugs act by blocking the 
ion channel formed by the M2 transmembrane protein, therefore preventing the 
acidification of the viral particle and precluding the release into the host cell cytoplasm of 
the vRNPs away from the viral matrix upon membrane fusion. Similarly, there are two 
neuraminidase inhibitors that are widely used in the clinic: Oseltamivir (Tamiflu®) and 
Zanamivir (Relenza®). These drugs act by inhibiting the enzymatic activity of the viral 
neuraminidase (NA) protein, therefore blocking viral release at the plasma membrane and 
preventing the spread of infection throughout the respiratory tract [26].  
Although the two types of drugs indicated above have proven helpful at preventing and 
treating complicated cases of influenza, and as prophylactic tools to prevent influenza 
transmission among members of the same household, their clinical use has been limited by 
the viral ability to develop resistance against them. Resistance against the Adamantanes in 
tissue culture settings was rapidly noted after their initial development, but it was not 
recognized as a real issue until 2003 when widespread resistance to Adamantanes was first 
observed among clinical viral isolates in the USA. By 2005, resistance to Adamantanes was 
so predominant that their use was discontinued [27]. This situation did not change as a 
consequence of the 2009 pandemic, as the M2 gene segment in the 2009 H1N1 pandemic 
virus originated from an Adamantane resistant strain. Therefore, today virtually all 
circulating influenza strains in the USA are considered to be resistant to Adamantanes and 
their clinical use is no longer suggested by the CDC [28]. Resistance to Oseltamivir was 
initially considered to be much more difficult to develop and disseminate among circulating 
strains, mainly because the mutations involved in providing resistance to it were thought to 
reduce transmissibility and overall viral fitness [29]. However, over 99% of all clinical 
isolates of H1N1 influenza virus during the 2008-2009 influenza season were found to be 
resistant to Oseltamivir during the 2008-2009 influenza season [30-31]. Luckily, the NA gene 
incorporated into the H1N1 2009 pandemic virus was derived from an Oseltamivir-
susceptible strain, and Oseltamivir resistance became substantially less predominant as the 
pandemic strain displaced and completely substituted the previous seasonal H1N1 strain. 
Nevertheless, resistance has already been reported among several clinical isolates of the 
currently circulating 2009 H1N1-derived influenza strain; therefore, it is likely that 
Oseltamivir resistance will become widespread among circulating viruses once again [32].  
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The vision that emerges from the brief review of our current anti-influenza arsenal 
presented above is one that emphasizes the need for alternative weapons. Vaccination will 
likely continue to play an essential role in minimizing the damaging effects of seasonal 
influenza, but unless we succeed in developing a truly universal anti-influenza vaccine, 
vaccination is unlikely to play a major role in the control of a highly pathogenic pandemic. 
Similarly, current antivirals may not be that useful either against a new pandemic due to the 
virus' ability to develop resistance against drugs targeting viral components. One promising 
alternative is to target cellular factors required for viral growth and multiplication for the 
development of new host-targeted antiviral agents [33-34]. One obvious drawback of this 
strategy is that drugs targeting host factors may exert toxic or substantial secondary effects 
in the host. However, host-targeted antiviral agents are likely to be effective against a broad 
range of viruses, (as most viral strains rely on the same cellular factors for their growth), and 
offer very limited chances for the development of viral resistance. In our opinion, these 
potential advantages associated to the implementation of host-targeted antivirals far 
outweigh their drawback and provide further justification for continuous investments 
aimed at a better understanding of influenza biology. 
1.5. A hot affair that is about to happen emphasizes the need for further basic 
research: A highly pathogenic bird virus is likely to generate the next influenza 
pandemic 
While many viruses are capable of producing severe disease in humans, few have the ability 
to generate pandemics with the potential to devastate human society. Influenza virus is one 
of them, and its ability to bring havoc into our society has been clearly demonstrated at least 
once in our recent historic record. The 1918 H1N1 "Spanish flu" influenza pandemic killed 
more than 50 million humans and probably infected over 30% of the human population at 
the time [35]. To date, the 1918 H1N1 pandemic is still considered the most damaging 
pandemic ever faced by humanity.  
The isolation and characterization of the full array of viral gene segments of the 1918 
pandemic virus, obtained from frozen and formalin-fixed tissue samples collected from 
victims of the 1918 pandemic, allowed the reconstruction of the virus [36]. This outstanding 
accomplishment has provided important insights into the molecular nature of the "Spanish 
flu" pandemic virus. Among others, those studies have revealed the relevance of specific 
gene segments, and of the full gene constellation as a whole, for the high pathogenicity 
exhibited by the virus (reviewed by Taubenberger and Kash [37]). However, numerous 
questions remain unsolved, including the origin of the virus. It has been postulated that the 
1918 virus likely resulted from the direct adaptation of a bird virus to humans, based on 
molecular signatures of its genome, such as the high GC content [38]. However, others 
consider it more likely that the virus had been introduced initially into swine, therefore 
allowing it to gradually become adapted to mammals [39]. In the absence of a viral 
repository that could provide detailed knowledge of the predominant viral strains in the 
years before the 1918 pandemic, it is very likely that the actual origin of the 1918 pandemic 
will remain unknown.  
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The lack of evidence demonstrating that the 1918 pandemic virus jumped directly from 
birds into humans, the apparent adaptation of all subsequent pandemic viruses (including 
the recent 2009 H1N1 "swine flu" pandemic) in swine before their introduction in humans, 
and the notion that only three HA subtypes (H1, H2, and H3) are normally observed in 
humans, out of  the sixteen different HA subtypes present in nature, helped maintain for 
decades the belief that avian influenza viruses could not be transmitted directly from birds 
to humans. This belief came to an end in May 1997 when a 3 year old boy in Hong Kong was 
infected and killed by what was subsequently determined to be an H5N1 avian virus [40-
41]. Subsequent events of direct transmission of H5N1 avian viruses into humans have 
accounted for up to 597 human cases reported to the World Health Organization (WHO) as 
of 19 March 2012, 351 of which have been lethal, for a mortality rate of about 59% [42]. 
Furthermore, direct transmission from birds to humans has also been reported for H9N2 
and H7N7 viral types[20].   
It has been calculated that the mortality rate for the 1918 pandemic was approximately 2.5% 
[35]. Therefore, the apparent pathogenicity of H5N1 viruses for humans, suggested from the 
number of lethal cases, appears to surpass by a wide margin that of the 1918 "Spanish flu". 
However, the real mortality rate associated to H5N1 infections may be orders of magnitude 
lower, as suggested by numerous studies performed on the prevalence of antibodies against 
H5 (a measurement indicative of exposure to H5N1 viruses) among individuals in regions 
where clinical cases of H5N1 influenza have been reported [43]. Nevertheless, the high 
pathogenicity of the H5N1 virus for humans is unquestionable.  
The factor that has precluded H5N1 from triggering a highly pathogenic human pandemic 
is its inability to be efficiently transmitted among humans. It has been almost 15 years since 
the first demonstrated case of direct transmission of H5N1 to humans, and throughout this 
time there has been arguably only one case of apparent direct H5N1 transmission among 
humans [44]. This suggests that it might be extremely difficult for the virus to become fully 
adapted for human transmission. Unfortunately, this may not be the case: Two recent 
reports, one published in Science by the group lead by Dr. Fouchier [45], and one published 
in Nature by the group lead by Dr. Kawaoka [46], and whose publication triggered 
substantial controversy due to the potential dual use of the data reported [47], provide proof 
that a few mutations affecting a limited number of viral gene segments are sufficient to 
allow highly pathogenic H5N1 viruses to become capable of direct transmission among 
ferrets, the animal model that best recapitulates the major features of influenza virus 
infections in humans . As the mutations identified in the Nature and Science reports could 
evolve spontaneously among viruses that propagate in the wild, these reports stress the 
relative high likelihood that humanity may face a highly pathogenic H5N1 pandemic 
sometime in the future. Importantly, other studies have also indicated that the novel 2009 
H1N1 "swine flu" exhibits high genetic compatibility with highly pathogenic H5N1 viruses 
[48], thus also increasing the odds of H5N1 producing a human adapted high pathogenicity 
strain via reassortment with 2009 H1N1. Considering the weaknesses of our current anti-
influenza defenses, these observations emphasize the utmost relevance of intensifying basic 
research in influenza biology with the goal of identifying and developing new prophylactic 
and therapeutic options against this virus.  
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2. Transcription and replication of the influenza virus genome 
In the 1970’s, Stephen C. Inglis, from the University of Cambridge at England, was the first 
to discover that the Influenza viral polymerase was a heterotrimeric protein complex 
composed of PB1, PB2, and PA. Later, further studies determined that NP, which 
encapsidates vRNA or complementary RNA (cRNA), forms large RNA-protein complexes 
when it associates with a viral polymerase and a cRNA or vRNA segment. In the past 40 
years, the extensive characterization of each subunit of the viral polymerase, including NP, 
and the conserved sequences of the vRNA gene segments have provided substantial 
information contributing to our knowledge of the mechanisms employed by Influenza A 
virus for transcription and replication. However, despite the collective efforts of the 
influenza scientific community, some ambiguity still exists about how some steps take place 
during viral transcription and replication. In order to achieve a complete and detailed 
molecular knowledge of these processes, it is important to keep in perspective the basic 
knowledge previously established by the founders of the field and the most recent findings 
related to the regulation of the viral polymerase, all of which are briefly presented below. 
2.1. The engine behind a pathogenic machinery: Nuclear accumulation and 3D 
structure of the viral RdRp  
The release of the vRNPs from the infectious viral particle is perhaps the most critical step in 
the initiation of viral replication. This event requires the acidification of the viral particle 
core for the disruption of the intermolecular interactions shared between the vRNPs and the 
M1 viral protein [49]. The viral complex responsible for the acidification of the virion’s core 
is the one formed by the tetramer of the M2 viral protein, which constitutes the smallest ion 
channel discovered to date [50]. The acidic environment then triggers the HA-mediated 
fusion of the viral and endosomal lipid bilayers [51-53], which allows the free vRNPs to 
migrate from the virion’s core into the cytoplasm of the infected cell. Since influenza 
transcription and replication take place in the cell nucleus, the incoming vRNAs must then 
be imported into the nucleus, a process mediated by two nuclear localization signals (NLS) 
present in NP, (spanning residues 1-13 [NLS1] and residues 198-216 [NLS2]) [54]. Recent 
studies, performed using digitonin-permeabilized cells in the presence of exogenous cytosol 
and energy-regenerating systems, have suggested that the directionality of nuclear traffic of 
the vRNPs during infection is determined by the exposure or masking of NLS1 in NP [55]. 
However, even in the presence of an antibody against NLS1 in NP, vRNPs still migrate to 
the nucleoplasm, indicating that NLS2 in NP also contributes to the nuclear accumulation of 
vRNPs [54]. Additional studies are needed in order to assess the contribution of NLS2 in NP 
during the nuclear accumulation of the vRNPs.  
The nuclear transport of the de novo synthesized viral polymerase proteins takes place in a 
highly organized manner and is critical for viral transcription and replication. The nuclear 
transport of PB2 occurs in the absence of any additional viral protein, while dimerization of 
PB1 and PA in the cytoplasm is required for their efficient nuclear trafficking [56-58]. Recent 
fluorescence cross-correlation spectroscopy (FCCS) studies demonstrated that the trimeric 
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structure of the RdRp is only present inside the cell nucleus [57]. This finding led to the 
discovery of a new function for the N-terminal domain of PA; preventing the formation of 
these trimeric structures in the cytoplasm [59]. Unfortunately this inhibitory mechanism has 
not been fully characterized, but it is speculated that the flexible linker region separating the 
N- and C-terminal domains of PA allows for a conformational change that prevents binding 
of PB2 while residing in the cytoplasm. Should this be true, it would then be important to 
characterize the molecular mechanism triggering the conformational change in PA that 
takes place upon its entry in the nucleus.  
The three subunits comprising the viral RNA-dependent RNA-polymerase (RdRp) are 
encoded by the three largest vRNA gene segments of Influenza A virus. PB2 is the largest 
subunit of the polymerase and the carrier of the 7-methylguanosine 5’-cap binding site [60]. 
The second largest subunit in the viral polymerase is PB1, and this is the only subunit that 
has the four conserved amino acids distributed among four different motifs present in all 
RNA-dependent RNA-polymerases and RNA-dependent DNA-polymerases [61]. Lastly, the 
smallest subunit, PA, has a characteristic PD-(D/E)-XK motif present in type II 
endonucleases, and is responsible for the cleavage of the 5’-cap of cellular mRNA [62-63]. 
These three viral factors form a very compact protein complex that still manages to maintain 
a high degree of flexibility.  
Several different 3D conformations have been observed using cryo- and negative staining 
electron microscopy for the purified recombinant influenza viral polymerases in the 
presence or absence of vRNA, NP, and both [64-67]. Those studies demonstrated that the 
polymerase has a globular hollow conformation that becomes compacted upon association 
with vRNA alone or vRNA in the presence of NP oligomers [64-67]. Additionally, PB1, PB2, 
and NP have been identified as the main viral proteins mediating the RNA-dependent 
interaction of the viral polymerase and the RNA-protein complex formed between NP and 
vRNA [65]. The diverse array of quaternary structures portrayed by the molecular 
structures predicted for the viral polymerase in the studies mentioned above, provide strong 
evidence of the existence of multiple conformational stages for the polymerase, likely 
associated to its various functional properties during transcription and replication. 
However, multiple other structures such as those associated to the cRNA-bound stage, the 
5’-cap interacting stage, and the oligomeric stage formed by the polymerase inside the 
nucleus, still remain unresolved.  
2.2. Transcribing the blueprint to assemble the engine: Viral mRNA 
transcription 
The transcription of the viral genome begins as early as one hour post-infection and takes 
place inside the cell nucleus [68] (Figure 2A). Early during infection, transcription of viral 
mRNAs is coupled to their translation and seems to plateau at 2.5 hours post-infection, 
whereas viral protein translation continues increasing throughout infection [68]. This 
provides evidence that a not fully characterized post-transcriptional regulatory mechanism 
ensures continued translation of the mRNA produced early during infection. Given that 
Influenza depends on the endogenous 5’ cap-dependent cellular ribosomal machinery to 
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translate its gene products, influenza has developed a mechanism called “cap-snatching” to 
prime the synthesis of all viral mRNAs [69]. According to in vitro reconstitution assays the 
cap-snatching event seems to be dependent upon binding of the viral polymerase complex 
on the viral promoter at the 3’-end of vRNA molecules [63, 69-70]. This interaction between 
the viral RdRp and the 3’-end of the vRNA triggers a conformational change within the 
RdRp, and allows PB2 to bind the 7-methylguanosine 5’-cap from cellular mRNAs [60, 69]. 
Additionally, the interaction between the viral RdRp and the cellular mRNA brings into 
close proximity the cellular 5'-cap with the PD-(D/E)-XK motif in PA, which then 
enzymatically cleaves 9-17 nucleotides downstream of the 5’-cap at guanine or adenine 
residues [63, 71] (Figure 2B). Through the use of site directed mutagenesis, vRNP 
reconstitution assays, and primer extension analysis it has been further shown that the 
coordination of a divalent ion (preferably manganese or magnesium) by the N-terminal 
domain of PA is required for the cap-snatching event [62-63]. The divalent cation required 
for the endonucleolytic activity of PA is stabilized by a cluster of four residues (H41, E80, 
D108, E119) residing in the N-terminal domain of PA [62-63]. Moreover, the crystal structure 
of these four residues seems to be unusually distant from the catalytically active Lysine 
residue at position 134, when compared to other crystal structures of type II endonucleases 
[62-63]. As mentioned above, the 5’-cap from cellular mRNAs is used by the viral 
polymerase to prime the transcription of viral mRNA during infection [69, 72](Figure 2C). 
This phenomenon has been demonstrated by in vitro transcription assays in which the 
chemical removal of the 5’-cap from -globin mRNA abolished the synthesis of viral mRNA 
[72]. Consistently, recapping of the -globin mRNA through the use of a Vaccinia virus 
guanylyl or methyl transferase rescued the production of IAV mRNA [72].  
While the 5’-cap from cellular mRNAs primes the transcription of viral mRNAs, the 
addition of ~150 adenines at the 3’ end, independent of the cellular poly-adenylation 
machinery, finalizes viral mRNA elongation. Polyadenylation of viral mRNAs is mediated 
by “stuttering” of the viral polymerase upon reaching a uridine-rich sequence usually made 
of 5-7 uridines, located 17 to 22 nucleotides away from the 5’ end of the vRNA template [73] 
(Figure 2D). At first, it was hypothesized that the formation of a panhandle structure 
between the complementary regions located at the 3’ and 5’ ends of the vRNA created 
sufficient steric hindrance to prevent the viral polymerase from transcribing the complete 
vRNA molecule, allowing the polyadenylation of viral mRNAs [73-74].  Later, in vitro 
transcription assays, performed using vRNA segments with various point mutations at the 
5’-end as templates for transcription, determined that the formation of a duplex between the 
3’- and 5’-ends of the vRNA, along with the binding of the viral polymerase to the 5’-end of 
the vRNA are both required for transcription [75]. This finding led to a refined hypothesis in 
which the viral polymerase binds to the panhandle structure formed between the 
complementary regions of the vRNA, recognizes the viral promoter, and subsequently 
elongates viral mRNA transcripts while remaining bound to the 5’-end of the template [75]. 
Because the viral polymerase is bound to the 5’-end of the template throughout the course of 
transcription, the viral polymerase is not capable of transcribing the 5’-end of the vRNA 
[75]. In other words, upon reaching the uridine-rich region at the 5’-end of the vRNA, the 
restraints inflicted by the intermolecular interactions shared between 5’-end of the vRNA 
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and the viral polymerase will produce polymerase stuttering, and this in turn will allow 
polyadenylation to occur [75]. Subsequent studies proved that transcription of viral mRNA 
was mediated primarily by the incoming vRNP-bound polymerase and not by polymerases 
added in trans [76]. This unexpected but important data was obtained during vRNP 
transfection experiments in which the transcription of viral RNA introduced into the cell as 
a component of purified vRNPs formed in the presence of a mutated (transcriptionally 
inactive) PB2 subunit could not be rescued by the addition of recombinant functional 
polymerases [76]. Moreover, vRNP co-transfection experiments have shown that the 
transcription of viral gene segments could not take place by polymerases present on 
adjacent vRNPs [76]. Altogether, the results discussed above strongly suggest that 
transcription of viral mRNA is driven by the polymerases that accompany the vRNA into 
the nucleus in the form of vRNPs early during infection. 
 
Figure 2.  
2.3. The time and place to make the mistakes that might help future viral 
generations: Viral genome replication 
The replication of the influenza virus genome requires the vRNA to first be transcribed into 
an additional type of viral RNA known as complementary RNA (cRNA). cRNA has a 
positive polarity and, as its name implies, it possesses a sequence that is complementary to 
that of the vRNA molecule. It is imperative for genome replication that the cRNA molecule 
contains the complete sequence of the vRNA, since it will be used as the template that will 
drive the synthesis of new vRNA late during infection. Early studies demonstrated that, in 
sharp contrast with the transcription of mRNA, the transcription of cRNA can be initiated in 
a primer-independent manner, while also using the same 13 and 12 nucleotides at the 5’- 
and 3’-end of the vRNA respectively as a promoter for transcription [77-78]. However, 
despite cRNA molecules being used for the replication of the viral genome, the 
accumulation of cRNA is very limited at early time points during infection [77]. It was also 
shown that the transcription of complete vRNA segments from cRNA templates could not 
be achieved in the absence of NP during in vitro transcription assays [79]. Subsequently, it 
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was demonstrated that the absence of cRNA at early time points post-infection could be 
explained by the lack of free NP protein early during infection, because the artificially 
driven expression of NP within the cell before infection allowed the accumulation of cRNA 
at early time points post-infection [80]. The model developed based on these observations 
proposed the formation of a “stabilization complex”, in which the binding and coating of 
the cRNA molecule with NP monomers prevents its degradation by cellular RNAses [80]. 
Surprisingly, even after 30 years of research, not very much information has been gathered 
on the molecular mechanisms involved in the elongation of cRNAs or how the steric 
hindrances faced by the viral polymerase during transcription are evaded to permit the 
complete transcription of the cRNA segment.    
2.4. Knowing when to stop and accelerate leads to a more pathogenic 
performance: Mechanisms regulating transcription and replication 
The meticulous orchestration of the multiple molecular complexes formed between the viral 
polymerase, vRNA, cRNA, other viral proteins, and cellular factors throughout the various 
steps during viral transcription and replication, provides additional molecular targets and 
mechanisms to regulate the activity of the RdRp. Those interactions are constantly 
triggering conformational changes on the flexible structure of the viral polymerase, which in 
turn dictate the specific functionality that it should exert. In order to further exemplify how 
different molecular interactions can exert a regulatory function on the viral polymerase, the 
structure of the viral promoter and the role of other viral proteins interacting with the RdRp 
will be discussed briefly below.   
i) The structure of the viral promoters: Through the use of Nuclear Magnetic Resonance 
(NMR) and calculations for determining the 3D structure of the vRNA promoter, it has been 
shown that the vRNA promoter has a terminal stem, followed by an internal loop, and a 
proximal stem [81-82]. The terminal stem displays an inherent bend that allows the viral 
promoter to be easily melted, therefore possibly playing a regulatory role during the 
initiation of RNA synthesis [82]. This intrinsic bending of the terminal stem might be of 
great relevance for transcription initiation, since the viral RdRp does not appear to have a 
helicase activity associated to it [82]. Additionally, the nucleotides involved in the formation 
of the internal loop within the vRNA promoter correspond to the same nucleotides 
previously identified as the binding sites for the viral RdRp [82-83]. Most of the residues 
constituting the internal loop have a highly dynamic structure and their binding to the viral 
polymerase creates an energetically favorable reaction by reducing the high entropy 
displayed by this structure [82]. Therefore, it is suggested that this internal loop in the 
vRNA promoter positions the catalytic core of the viral polymerase at the transcription 
initiation site [82].  
The structure of the cRNA promoter used for genome replication has also been determined 
by NMR and exhibits a somewhat comparable but very distinct structure to that of the 
vRNA promoter [84]. Importantly, the structural differences between the two viral 
promoters might allow the viral polymerase to distinguish between the transcription of 
mRNA/cRNA and vRNA [84]. This idea is further supported by the fact that the viral 
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polymerase binds to the cRNA promoter through the central region of PB1, while the vRNA 
promoter interacts with the C-terminal region of PB1 [85]. Interestingly, in both cases the 
internal loop regions of the vRNA and cRNA are involved in the binding of the RdRp, 
suggesting that the structure of the internal loop might be more relevant than the actual 
sequence itself for positioning the viral polymerase to initiate transcription [84-85]. 
Nonetheless, even though the internal loop regions share general structural similarities, 
their individual conformations are quite distinct. The comparison of both structures showed 
that the internal loop of the cRNA promoter is very unstable when compared to the internal 
loop present in the vRNA promoter [84]. The lack of stability of the internal loop region in 
the cRNA is due to the improper stacking of the bases belonging to the nucleotides located 
in that region, which contrasts sharply with the proper stacking observed for the nucleotides 
located in the equivalent regions of the vRNA promoter [84]. However, the relevance of 
such great difference in stability for both the vRNA and cRNA loop regions still remains 
unknown.  
ii) Viral proteins involved in the regulation of the viral polymerase: As mentioned above, 
viral proteins different from those constituting the vRNP complexes can also play an 
important regulatory role in the function of the viral polymerase. To date, the molecular 
mechanisms underlying the viral polymerase switch from transcription to replication still 
remain unresolved. However, the involvement of several viral factors has been 
characterized to some degree. So far, only one viral protein has been identified as a regulator 
of the transcriptase activity of the viral polymerase. Primer extension analyses, have shown 
that the mRNA/vRNA ratio generated during vRNP reconstitution assays performed in the 
presence of NP and the viral RdRp (but no other viral protein) is  substantially larger than 
the mRNA/vRNA ratio normally generated during viral infection [86].  Testing the effect of 
overexpressing individual Influenza A viral proteins on the transcription of multiple vRNA 
gene segments during vRNP reconstitution assays allowed the identification of a 
transcriptional regulatory function associated with NEP [86]. Subsequently, it was shown 
that the presence of NEP leads to the generation of Influenza A virus-derived small viral 
RNAs (svRNA) [87]. These svRNAs correspond to the 5’-end of each vRNA genomic 
segment and have different lengths, ranging from 22 to 27 nucleotides, depending on the 
gene segment they are derived from, and seem to interact directly with the viral polymerase 
[87]. More importantly, their accumulation in the cell is coupled to a shift from viral 
transcription to replication, while their depletion results in loss of vRNA synthesis for their 
parental gene segment [87]. These results suggest that these svRNAs prime the initiation of 
transcription for genomic vRNA, as previously observed in cellular DNA-dependent RNA-
polymerases. Altogether, both NEP and svRNAs seem to be playing a critical role in the 
switch from transcription to replication. Nevertheless, no direct interaction between the 
polymerase and NEP has been observed through the use of immunoprecipitation assays, 
therefore leaving the exact molecular mechanism involved in this regulatory process 
unresolved. An important lesson derived from these studies is that, in the absence of 
supplementary proteins (e.g. NEP) the limited number of viral factors (PB1, PB2, PA, and 
NP), commonly employed during vRNP reconstitution assays, might prevent us from 
realizing the authentic effects imposed by chemical inhibitors or point mutations on the 
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transcriptase activity of the RdRp, since under such conditions these assays do not 
accurately recapitulate the events involved in viral transcription and replication during 
influenza infections. 
3. Cellular factors important for viral multiplication 
The first identification of cellular factors involved in influenza viral infection took place as 
early as 1959 [88]. However, up to fairly recent times, most studies related to influenza 
replication and multiplication focused exclusively on the mechanistic assessment of 
processes mediated by viral proteins and put little emphasis on the cellular factors or 
pathways involved in influenza replication. During the last few years, the use of multiple 
approaches such as protein pull-downs, chemical inhibition studies, yeast-two hybrid 
screening, affinity purification, and RNA interference (RNAi), have led to the identification 
of multiple cellular factors essential for influenza viral replication [89-97]. In the sections 
below, we will review the most recent findings related to the relevance of specific host 
cellular proteins and systems for influenza transcription and replication. Despite the 
substantial progress achieved during the last few years, the overall status quo of the field is 
that the functions of the characterized viral-cellular protein interactions remain mostly 
unclear. Table 1 summarizes the cellular factors required for influenza replication discussed 
in this section. 
3.1. Downloading a virus: Viral egress from endocytic vesicles 
In order for the vRNPs to reach the nucleus, which constitutes their final destination within 
the host cell, they have to be released from the incoming viral particle. This process requires 
the acidification of the viral particle and fusion of the endosomal and viral membranes. The 
decrease in pH within the endosomal compartment requires the cellular vacuolar proton 
ATPases (v-(H+)ATPase) to hydrolyze ATP and transport protons inside the vesicle [98]. 
Three large screenings for cellular factors relevant for influenza infection, performed by Hao 
et al. [91], Konig et al. [92], and Karlas et al. [95], identified members of the v-(H+)ATPase 
family as critical host factors required for the progression of influenza infection. Before the 
screenings, it had been established that treatment of cells with concanamycin A, a well 
known inhibitor of v-(H+)ATPases, was enough to halt the production of viral proteins at an 
early stage post-infection. However, the addition of concanamycin A one hour after 
infection had no effect on the production of viral proteins, suggesting that the inhibition of 
endosome acidification affected only the earliest stages of viral infection [99]. Subsequent 
studies using diverse inhibitors and RNAi approaches confirmed the involvement of v-
(H+)ATPases in early stages of infection [100-101] and provided further details of their 
specific role during influenza infections [102].  Studies by Marjuki et al. [102] revealed that, 
upon entering the cell, influenza activates the ERK and PI3K pathways. These pathways 
activate the E subunit of the v-(H+)ATPase V1 domain, upregulating its proton pumping 
activity and leading to a more rapid acidification of the endosome [102], a process needed 
for the fusion of the viral and endosomal membranes.  
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The non-clathrin-coated vesicular coat COP-I proteins have also been identified as 
important cellular factors required for efficient viral replication in three large viral-cellular 
interaction screenings (Table 1.), thus supporting a relevant role for this protein family in the 
influenza life cycle. However, it is still uncertain the specific events in the viral life cycle that 
are affected by this protein family. Because one of the screenings that identified the COP-I 
proteins as relevant for viral infection used the transcription of early viral genes as output, 
and the known role of COP-I proteins in retrograde traffic of Golgi vesicles back to the ER 
[103],  it is likely that the COP-I proteins are necessary for some stage of viral entry. 
Onward from endocytosis of the viral particles, it has been suggested that a member of the 
lysosome-associated membrane glycoprotein family, LAMP3, is involved in the release of 
the vRNPs from the endosomal compartments and in facilitating vRNP nuclear import. 
However, the hypothetical pivotal role suggested for LAMP3 during infection is somewhat 
surprising, since LAMP3 is interferon induced and up-regulated during viral infection and 
therefore expected to exert an anti-viral activity. Nevertheless, siRNA knockdown of 
LAMP3 significantly reduced levels of NP expression during infection [104], thus 
supporting the enhancing role postulated for LAMP3. 
3.2. A molecular hijacker: Nuclear shuttling of vRNPs 
Once inside the cytoplasm, viral RNA transcription begins only upon arrival of the viral 
ribonucleoprotein (vRNP) complexes into the nucleus. The shuttling across the nuclear pore 
complex of both, the largest macromolecular complexes formed by the virus during 
infection, i.e. the vRNPs, as well as of its individual protein components, rely on the cellular 
nucleocytoplasmic trafficking machinery. The importin α/β pathway is the classical nuclear 
import pathway, transporting cargo proteins from the cytoplasm into the nucleus upon 
recognition of a nuclear localization sequence (NLS) by karyopherins, typically importin . 
Most cargo proteins directly interact through their NLS with the adapter protein importin α, 
which then binds importin β for nuclear import. Transport of the importin /-cargo protein 
complex is facilitated by interactions with nucleoporins (Nups), the structural components 
of the nuclear pore complex [105]. Expectedly, Nups were one the major categories of factors 
identified in large scale screenings for cellular proteins required for efficient influenza 
infections, having been identified in 4 different screenings [92-93, 95, 97]. Their fundamental 
role as regulators of nucleocytoplasmic traffic allows them to dictate the nucleocytoplasmic 
transport of viral transcripts, proteins, and RNPs.  
The PB2 and NP viral proteins have been shown to interact with importin α1 for their 
nuclear trafficking. As previously described, NP contains two NLS, both of which are of 
great relevance for proper nuclear import of vRNPs, since mutating either of the two NLS 
domains results in decreased accumulation of vRNPs within the nucleus [54]. As for PB2, its 
interaction with importin 1 was initially characterized through targeted mutations in the 
aspartic acid at position 701 and asparagine at position 319. These two point mutations on 
PB2 have the ability to further enhance its affinity for importin α1, and consequently, its 
nuclear accumulation [106]. Furthermore, studies using Fluorescence Cross-Correlation 
Spectroscopy (FCCS), in which the live transient trafficking of transiently expressed viral  
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Table 1. Summarized Host Factors Involved in Influenza Replication and Viral Processes. 
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proteins is recorded, confirmed the interaction between PB2 and importin α during its 
nuclear import. In contrast with the use of the classical nuclear traffic pathway by PB2, the 
FCCS studies also noted that nuclear traffic of the remaining viral polymerase subunits (PB1 
and PA) occurs through a non-conventional importin α-independent pathway [57], with 
PB1 forming a heterodimer with PA, which is required by PB1 and PA to gain access to the 
nucleus (as stated in section 4a) and using it in conjunction with Ran binding protein 5 
(RanBP5) as the carrier [107].  
3.3. Someone’s in the kitchen: Cellular dependent transcription and vRNA 
synthesis  
The activation of RdRp driven vRNA transcription relies heavily on the host cell 
transcriptional machinery. Four different viral-host interaction screenings [89, 93, 95, 97] 
identified subunits of the cellular RNA Polymerase II (Pol II), which further reinforced 
previous work performed on the proposed mechanisms for the role of Pol II on viral 
transcription. During the normal cycle of cellular RNA transcription, the promoter 
associated Pol II is phosphorylated by TFIIH to initiate transcription. Transcription, 
however, can be temporarily paused by negative elongation factors, allowing time for the 
addition of the 5’ cap to the short segment of pre-mRNA transcript already synthesized. 
Subsequent phosphorylation of the C-terminal domain of the paused Pol II, mediated by P-
TEFb, relieves the pause and re-activates transcription [108]. Before the onset of viral 
transcription, the viral PB2 protein, in association with PB1 and PA, is brought into close 
proximity to the cellular Pol II by TFIIH, allowing it to bind the 5’-cap structure of a cellular 
pre-mRNA transcript [109]. As described in the previous section, PA steals the 5’-cap along 
with a 9-17 nucleotide extension in a mechanism referred to as “cap-snatching.” The 5’-cap 
oligonucleotide then serves as a primer for the polymerase subunit of the RdRp, PB1, to 
initiate vRNA transcription and elongation [110]. Elongation ends when the RdRp reaches a 
5 to 7 uridine base-pair extension towards the 5’ end of the vRNA template, which signals 
for polyadenylation of the transcript [111-112]. Cell splicing factors also appear to be vital 
for efficient vRdRp-dependent transcription of the viral genome. In a reporter assay, 
knockdown of the nuclear Splicing Factor Proline-Glutamine Rich (SFPQ/PSF) reduced 
levels of viral transcription, but had no effect on viral genome replication. Moreover, in vitro 
analysis of viral transcription revealed about a ~5-fold reduction in the fraction of viral 
polyadenylated (positive sense) transcripts, suggesting that SFPQ/PSF seems to facilitate the 
polyadenylation of viral transcripts [113]. UAP56, (Bat1/Raf-2p48), a known viral-interactor 
protein that was also identified in a vRdRp interaction screening by Mayer et al. [89], is a 
fairly well established RNA helicase involved in spliceosome assembly [114], facilitating the 
nuclear export of cellular mRNA [115], and is a constituent of the transcription export 
complex which delivers pre-mRNAs bound to the exon-junction complex to nuclear export 
factor 1 (NXF1) [116]. Although UAP56 is clearly a factor in cellular RNA splicing, in vitro 
studies indicate that UAP56 forms heterodimers with NP in the absence of vRNA. Upon 
addition of vRNA the heterodimer dissociates and, through an unknown mechanism, 
facilitates vRNA synthesis [117] suggesting higher affinity interaction of one of these 
proteins for vRNA. Altogether, this not only suggests a pro-viral functionality of UAP56 in 
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enhancing vRNA production, but that efficient viral replication exploits multiple 
functionalities of cellular host factors in a well orchestrated manner. 
3.4. Cutting and mincing the viral transcripts: Host splicing machinery and 
influenza viral RNA 
Splicing of viral mRNA, needed for the production of M2 and NS2, is fully dependent on the 
host splicing machinery due to the lack of splicing factors encoded within the viral genome. 
However, the splicing of the M viral segment to produce the M2 transcript is orchestrated 
by both viral and cellular components. CDC-like kinase 1 (CLK1), a protein responsible for 
the regulation of pre-mRNA splicing, plays a key role in the production of M2 vRNA 
spliced transcripts as demonstrated through RNAi knock-down and chemical inhibition 
studies [95]. CLK1 has been implicated in regulating the splicing of M1 mRNA [95], by 
phosphorylating the serine/arginine rich splicing factor, SF2/ASF [118]. SF2/ASF is a 
member of the serine/arginine rich splicing factor family, which are key factors in both 
alternative and constitutive pre-mRNA splicing, (reviewed in [119]) and is a critical splicing 
factor involved in the production of M2. Although cellular transcripts most often rely on 
consistent excision of intronic sequences, influenza virus replication depends on precise 
proportions of spliced and unspliced transcripts, as observed in the processing of the M1 
mRNA transcript. For the duration of infection, splicing factor SF2/ASF is associated to a 
purine-rich enhancer sequence on the 3’ end exon of the M1 transcript. In early stages of 
infection, the 5’ mRNA3 splicing donor site of the M1 RNA transcript is the highly preferred 
splicing donor site by the host splicing machinery, thus causing the disfavored M2 5’ splicing 
donor site, ~40 nucleotides downstream, to be ignored. As infection progresses, a newly 
synthesized viral RdRp binds the 5’ end of the unspliced M1 mRNA, blocking access of the 
cellular splicing machinery to the mRNA3 5’ end splice donor site. [120]. The host splicing 
machinery then associates with the M2 5’ splice donor site, awaiting activation by SF2/ASF to 
initiate production of M2 mRNA transcripts [121]. Host splicing factors involved in the 
processing of the eighth gene segment, NS segment, have yet to be specified. Although it 
appears that the competition between the splicing machinery and the nucleocytoplasmic 
transport machinery regulate the production of NEP, it has been established that viral factors 
associated with viral infection do not regulate splicing of the NS transcript [122-123].  
3.5. Unexpected delivery: Nuclear export of Viral mRNA and the vRNP 
Since IAV has the unique capability among RNA viruses of replicating in the nucleus, there 
are additional processes such as viral mRNA and vRNP nuclear export that are essential for 
viral infection. Due to the nature of the “cap-snatching” event that takes place during 
infection, nuclear cap-binding complexes have the ability to interact with viral mRNAs and 
aid in the recruitment of nuclear export regulatory factors such as REF/Aly [124]. This was 
shown through the use of simple interaction studies in which viral mRNA was able to co-
immunoprecipitate with translational machinery factors such as cellular cap binding 
proteins, RNA and export factor-binding protein REF/Aly, cellular poly(A)-binding protein 
1 (PABP1), the 20 kDa subunit of the nuclear cap-binding complex (NCBP2), and the 
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eukaryotic translation initiation factor 4E (eIF4E) [124]. Additional cellular factors involved 
in viral mRNA nuclear export were also identified by multiple RNAi screenings. These 
studies revealed that independent viral mRNA transcripts exploit specific nuclear export 
factors for their individual export into the cytoplasm. It was not surprising that NXF1, a 
cellular protein involved in the nuclear export of cellular mRNAs, was found to be of 
relevance for influenza replication in three independent screenings [91, 93-95]. siRNA 
knockdowns against NXF1 revealed that mRNAs coding for the early protein NS1, and the 
late proteins HA, NA, M1, and M2, depend on NXF1 for their nuclear export [91, 93-95]. The 
mRNAs encoding for the viral polymerase proteins PB1, PB2, PA, and NP also show 
dependence on NXF1 for their nuclear export, but to a lesser extent [125]. On the other hand, 
the nuclear export of mRNAs coding for M1, M2, and NS1 show dependence on the 
previously mentioned RNA helicase, UAP56, for their efficient nuclear export [126]. The 
dependence of these transcripts on UAP56 was demonstrated by knocking down UAP56, or 
its high sequence identity paralog URH49. The limited availability of either UAP56 or 
URH49 triggered an accumulation of influenza dsRNA at the nuclear membrane and an 
increase in IFN production [126]. However, even when the multiple RNAi screenings have 
identified cellular factors like NXF1 and UAP56 as essential for viral mRNA nuclear export, 
additional factors such as those involved in the nuclear export of the mRNA for NEP still 
remain unknown. Also, we still need to identify the other proteins forming the complexes 
involved in nuclear export of viral mRNAs, to facilitate the complete characterization of the 
molecular mechanism driving this fundamental process. 
As mentioned above, vRNP nuclear export is also a process of great relevance for the 
assembly of infectious viral particles. So far, we know that mature vRNP complexes depend 
on the CRM1 pathway for their nuclear export. CRM1 mediated nuclear export is carried 
out through the recognition of a nuclear export signal (NES) present in the amino acid 
sequence of the cargo protein [127]. In the case of the vRNPs, CRM1 binds to the NES 
located at the N-terminal region of NEP. Interestingly, after mutating the NES present in 
NEP, its nuclear export was impaired without affecting its interaction with CRM1 [13]. 
Crystallographic studies of the M1 binding domain present in NEP suggested that the 
nuclear export of vRNPs required the formation of a “daisy-chain complex” in which, 
RanGTP-loaded CRM1 associates with the N-terminal NES of NEP, and NEP is associated 
via its C-terminal domain to an M1 molecule bound C-terminally to the vRNP [128]. 
Furthermore, several studies have identified a structural component of the nuclear pore 
complex involved in CRM1-dependent export, Nucleoporin 98 (Nup98), as a critical host 
factor during influenza A viral replication [91, 93, 95, 129]. A recent study demonstrated the 
interaction between a GLFG repeat domain located within the Nup98 protein and NEP 
[129]. This interaction suggests that Nup98 facilitates nuclear export of the vRNPs during 
influenza infection, via its interaction with NEP [129]. To confirm the relevance of the GLFG 
domain in Nup98 during viral infection, a mutant form of Nup98 lacking the GLFG domain 
was overexpressed by transfection and led to a substantial decrease in viral titers [129]. Even 
though the studies described above provide evidence that Nup98 is an essential cellular 
factor for viral infection, a more detailed knowledge of the molecular events mediating 
vRNP nuclear export is still missing.  
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Lastly, after leaving the nucleus, the vRNPs need to migrate towards the apical surface of 
the cell to become encapsidated into new virions. Previous studies demonstrated through 
the use of live imaging microscopy that, upon entering the cytoplasm, vRNP complexes 
associate with a pericentriolar recycling endosome marker called Rab11, which is involved 
in endosomal recycling and trafficking [130]. The accumulation of vRNPs at the 
microtubule-organizing center after nuclear export, allows them to interact with Rab11-
positive recycling endosomes and migrate along microtubules to the sites of budding at the 
apical surface of the plasma membrane [131-133].   
4. Influenza virus and the cellular SUMOylation system 
4.1. A cellular system with a funny name: Generalities of the SUMOylation 
system 
SUMOylation, the post-translational conjugation of the Small Ubiquitin-like MOdifier 
(SUMO) to a protein, involves the formation of an isopeptide link between the carboxyl 
group located at the C-terminal glycine residue in SUMO and the epsilon amino group in a 
lysine residue located internally in the target protein. There are four different SUMO 
molecules in humans, SUMO 1-4. SUMO2 and SUMO3 are 95% identical to each other, and 
in consequence are usually referred to simply as SUMO2/3, whereas SUMO1 shares only 
approximately 50% identify with them (reviewed by Geiss-Friedlander and Melchior [134], 
and Dohmen [135]). Besides their sequence differences, SUMO2/3 and SUMO1 appear to be 
functionally different as well: First, the pool of proteins that are SUMOylated with SUMO2/3 
is only partially overlapping with the pool of proteins that are SUMOylated with SUMO1 
[136-137]; second, SUMO2/3 is capable of forming poly-SUMO2/3 chains in vivo, whereas 
SUMO1 is not (reviewed by Ulrich [138]). The ability of SUMO4 to be conjugated to proteins 
in vivo is still being debated and therefore its biological role is still uncertain. 
The enzymatic pathway involved in SUMOylation resembles that required for the 
conjugation of its related protein, Ubiquitin, and consists of an E1 activating and an E2 
conjugating enzymes, a set of E3 ligases, and a set of SUMO-specific peptidases and 
isopeptidases (Figure 3). However, the specific enzymes required for SUMOylation are 
distinct from those involved in Ubiquitinylation, and therefore the Ubiquitin and SUMO 
pathways are independent from each other and subject to different regulatory mechanisms. 
Interestingly, while in the Ubiquitin pathway the conjugation of Ubiquitin to a substrate has 
an absolute requirement for the involvement of an E3 Ubiquitin ligase, in the SUMO 
pathway the E1 and E2 activities (performed by the heterodimeric protein SAE2/SAE1 and 
Ubc9, respectively) are sufficient for SUMO conjugation, without the absolute need for an E3 
SUMO ligase. Nevertheless, numerous E3 SUMO ligases have been identified and are 
considered to play an important regulatory role for the SUMOylation of specific targets in 
vivo (reviewed by Dohmen [135], Geiss-Friedlander and Melchior [134],  and Wilson and 
Heaton [139]). The SUMO peptidases and isopeptidases make SUMOylation a reversible 
modification, and their high intracellular concentration and activity is thought to be 
responsible for the low cellular concentration of the SUMOylated form for any given protein 
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(for most SUMO targets, the SUMOylated form of the target represents less than 5% of the 
steady-state cellular level of that protein) [140]. 
 
Figure 3.  
4.2. A "molecular matchmaker": The effects of SUMOylation on its target 
proteins 
SUMOylation is known to affect an ever increasing number of cellular proteins, some of 
which were initially identified as SUMO targets during large-scale proteomic analyses of 
cellular SUMOylation [136-137, 141-142]. The effects produced by this post-translational 
modification on its target proteins are numerous and appear to be protein specific. Among 
others, SUMO has been shown to alter its target proteins by affecting their cellular 
localization, protein stability/half-life, and protein activity (reviewed by Hay [140], Hilgart 
et al. [143], Gill [144], and Wilkinson and Henley [145]). The unifying theme behind the wide 
range of activities mediated by SUMOylation appears to be SUMO's ability to regulate the 
intermolecular interactions established between its targets and other macromolecules, 
sometimes enhancing them and sometimes blocking them. In either case, it seems that 
whatever the effect mediated by SUMO might be, its effects last longer than the actual 
SUMOylated state of the target. In other words, the protein interactions facilitated or 
prevented by SUMOylation are maintained even after the protein has been de-SUMOylated. 
A simple explanation for this fact is that SUMO may act as a "molecular matchmaker", 
introducing proteins to each other and allowing them to establish long-lasting interactions, 
probably stabilized by the recruitment of other protein partners that can only interact with 
the interacting pair but not with the individual members of the pair. Those long-lasting 
interactions remain even after a de-SUMOylating enzyme takes away the SUMO molecule 
that allowed the initial interaction. As a consequence, mutations affecting the ability of a 
protein to become SUMOylated will have dramatic effects on protein function, despite the 
fact that the SUMOylated form of the protein may represent only a small fraction of its total 
in the cell.  
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4.3. A post-translational modification known to wrestle with many infectious 
organisms: The interplay between the cellular SUMOylation system and various 
infectious agents  
While numerous infectious organisms are now known to interact with the cellular 
SUMOylation system by having some of their proteins being modified by SUMOylation, 
there are a few specific examples of infectious organisms that produce global changes in the 
activity of the cellular SUMOylation system. Interestingly, for such organisms capable of 
affecting the overall activity of the SUMOylation system, the predominant picture observed 
is their tendency to decrease both, the activity of the SUMOylation system and the overall 
number of SUMOylated proteins present within the host [146]. This trend suggests that the 
SUMOylation system may have an intrinsic effect as a cellular defense mechanism against 
some infectious agents. Two well characterized proteins encoded by two different infectious 
organisms, a virus and a bacterium, exemplify and support the predominant picture 
indicated above and, therefore, will be briefly discussed below.  
i) Gam1: Gam1 is a protein encoded by the so-called chicken embryo lethal orphan (CELO) 
avian adenovirus. This protein was initially characterized as an anti-apoptotic viral protein, 
as well as an inhibitor of the deacetylating enzyme HDAC1 [147]. Subsequently, it was 
observed that Gam1 was also capable of inducing both, the loss of Pro-Myelocytic Leukemia 
Nuclear Bodies (PML-NBs), a nuclear structure believed to play antiviral activities and 
whose formation depends on the SUMOylation of the PML protein, and a global decrease in 
host cellular SUMOylation [148]. Follow up studies demonstrated that Gam1 inactivates the 
heterodimeric SUMO activating enzyme SAE2/SAE1, therefore triggering its degradation by 
a proteasomal-dependent pathway. The degradation of the E1 activating enzyme for the 
SUMO pathway also leads to the degradation of the E2 conjugating enzyme, Ubc9, therefore 
producing a complete block in SUMOylation [149]. Importantly, Gam1 has been 
demonstrated to be essential for CELO viral growth and multiplication, therefore suggesting 
that the SUMO inhibitory activity mediated by Gam1 is essential for viral fitness [150].  
ii) Listeriolysin O (LLO): LLO is a pore forming toxin produced by the intracellular 
bacterial pathogen Listeria monocytogenes, the causative agent of human listeriosis. In a study 
aimed at evaluating the potential ability of L. monocytogenes to alter global cellular 
SUMOylation, it was observed that HeLa cells infected with this bacterium exhibited a 
dramatic decrease in global cellular SUMOylation. This was not true for HeLa cells infected 
with its non-pathogenic cousin L. innocua. Subsequent analysis of various bacterial mutants 
identified LLO as the factor responsible for the de-SUMOylating activity associated to L. 
monocytogenes. Specifically, LLO was shown to trigger the degradation of the E2 conjugating 
enzyme Ubc9, therefore leading to a global decrease in cellular SUMOylation. The relevance 
of this decrease for bacterial infection was demonstrated by showing that over-expression of 
SUMO1 or SUMO2 in HeLa cells before L. monocytogenes infection led to a substantial 
decrease in the number of intracellular bacteria produced by 7 h post-infection, thus 
supporting a role for decreased cellular SUMOylation in enhancing bacterial growth [151].  
In contrast with the examples presented above, there are also reports of proteins encoded by 
viral pathogens that are endowed with the ability to enhance the SUMOylation of specific 
 
Influenza A Virus Multiplication and the Cellular SUMOylation System 23 
cellular proteins as a way to regulate cellular systems that play an important role during 
viral infection. Two important examples of this type of interaction between viral agents and 
the SUMOylation system are presented below.  
iii) K-bZIP: The basic leucine zipper protein of Kaposi's sarcoma-associated herpesvirus 
(KSHV), K-bZIP, is one of the earliest proteins expressed after acute infection or reactivation 
by KSHV. K-bZIP, a transcriptional regulator of viral gene expression, was initially shown 
to interact with the SUMOylation system by acting as a SUMO target, being SUMOylated at 
residue K158. K-bZIP SUMOylation appeared to affect its transcriptional activity [152]. 
Subsequently, it was shown that K-bZIP contains a SUMO2/3-specific SUMO Interacting 
Motif (SIM) that allows K-bZIP to enhance its own SUMOylation and that of other cellular 
proteins known to interact with it, including the tumor suppressor proteins p53 and pRB 
[153]. In consequence, it has been postulated that K-bZIP acts as a viral encoded SUMO 
ligase that helps ensure the maintenance of the proper cellular environment needed for viral 
multiplication by triggering the SUMOylation and subsequent activation of p53, which in 
turn triggers cell cycle arrest in G1 [153].  
iv) VP35: The VP35 protein encoded by Ebola Zaire virus (EBOV) is one of two EBOV viral 
proteins known to be involved in suppressing the type I interferon (IFN) response in the 
cell. The mechanism responsible for IFN inhibition was postulated to involve VP35's ability 
to bind to dsRNA therefore preventing retinoic acid induced gene I (RIG-I) activation [154]. 
However, a mutant form of VP35 incapable of binding dsRNA was found to retain its IFN 
blocking activity, suggesting the existence of an alternative mechanism for IFN inhibition by 
VP35. Type I IFN production is ultimately triggered by the transactivational activity of NF-
κB and two additional transcription factors: Interferon regulatory factors 3 and 7 (IRF3 and 
IRF7, respectively). VP35 was demonstrated to interact with the SUMO ligase PIAS1, the E2 
SUMO conjugating enzyme Ubc9, and IRF7. Furthermore, VP35's ability to interact 
simultaneously with all of these factors was shown to enhance the SUMOylation of IRF7 and 
IRF3. In turn, the enhanced SUMOylation of IRF7 and IRF3 was demonstrated to diminish 
their ability to transactivate type I IFN production, therefore leading to a substantial 
decrease in type I IFN production during EBOV infection [155]. In consequence, VP35 
represents a viral protein that enhances the activity of a SUMO ligase as a way to neutralize 
the transcriptional activity of specific cellular factors, therefore leading to decreased type I 
IFN production and diminished cellular antiviral responses during infection, an outcome 
that favors viral multiplication. 
Altogether, the four proteins presented above, encoded by four different pathogens, 
exemplify some of the most important interactions established between infectious 
organisms and the cellular SUMOylation system and provide a framework to understand 
the potential roles played by SUMO during influenza virus infection.  
4.4. The beginning of the wrestling match: Initial insights into the relevance of 
the cellular SUMOylation system for influenza virus infections 
Our laboratory was arguably the first in studying the potential interplay between the 
cellular SUMOylation system and influenza virus. Our initial studies on this topic, dating 
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back to 2005, were motivated by the well established relevance of SUMO for the biological 
activities of numerous proteins encoded by DNA viruses [156]. The unifying theme at the 
time was that SUMO appeared to regulate numerous viral proteins targeted to the nucleus 
of the cell. Because influenza replication occurs in the nucleus of the infected cell, it seemed 
plausible that some influenza viral proteins would turn out to be SUMO targets. Our initial 
test of this hypothesis involved in vitro SUMOylation reactions in which 35S-methionine 
labeled viral proteins produced in a coupled transcription/translation system were 
incubated with a fully purified reconstituted SUMOylation system. The data produced by 
these experiments were surprising and unexpected as they showed that most of the 9 viral 
proteins tested were SUMOylatable in vitro. The only viral proteins that were not tested 
were PB1-F2 and M2, and the only two proteins that did not appear to be SUMOylated were 
the two membrane viral proteins tested, HA and NA [157].  
Although our personal experience has indicated direct correlation between in vitro 
SUMOylation and in vivo SUMOylation, it was necessary to demonstrate that the viral 
proteins identified as SUMO targets in vitro could also become SUMOylated when 
expressed in mammalian cells. This proved more challenging than expected, partially due to 
the limited pool of free SUMO normally present in the cell, and required the development of 
a set of dicistronic expression constructs capable of simultaneously inducing large increases 
in the cellular concentrations of SUMO accompanied by slight increases in the cellular pool 
of its conjugating enzyme Ubc9. The development and implementation of such dicistronic 
expression constructs allowed us to demonstrate that the non-structural influenza protein 
NS1 is a bona-fide SUMO target in vivo, being SUMOylated both, when over-expressed by 
transfection, as well as when expressed at normal physiological levels during viral infection. 
On the day this finding was published online, 14 November 2009, it constituted the first 
published report supporting the potential relevance of SUMOylation for influenza virus 
[158], and the dicistronic constructs described therein have subsequently been proven 
invaluable as key tools in numerous studies related to the SUMOylation of other cellular 
and viral proteins [157, 159-160].  
Just one month after the publication of our report, further evidence supporting an important 
role for the cellular SUMOylation system during influenza virus infection was provided by 
two papers reporting the outcome of large scale screenings aimed at identifying cellular 
proteins required for efficient influenza virus infection. In the first report, published online 
on 21 December 2009, König et al. reported the identification of SUMO2, SUMO1, and SAE1 
among the cellular genes whose down-regulation by RNAi in a human lung epithelial cell 
line (A549) led to a substantial decrease in viral transcription/translation, as assessed using a 
Renilla luciferase reporter system placed in substitution for the HA protein in a recombinant 
A/WSN/1933 H1N1 viral strain [92]. In the second report, published online on 24 December 
2009, Shapira et al. identified Ube2I (i.e. Ubc9, the SUMO conjugating enzyme) as one of the 
cellular proteins capable of establishing direct physical interactions with the viral proteins 
PB1 and NS1 derived from the A/Puerto Rico/8/1934 H1N1 viral strain, and the NS1 protein 
derived from the A/Udorn/307/1972 H3N2 viral strain. In that report, the significance of 
those interactions, initially detected during the implementation of a large yeast two hybrid 
screening for cellular proteins capable of interacting with viral proteins, was further 
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validated by using an RNAi approach [94]. Altogether, the two large scale screenings for 
cellular proteins required for efficient influenza virus infection confirmed the relevance of 
the SUMOylation system for influenza suggested by our initial studies.  
4.5. Wrestling with the interferon response of the host: Relevance of the cellular 
SUMOylation system for the biological functions of the non-structural viral 
protein NS1 
Almost exactly one year after the initial publication of our report on the SUMOylation of 
NS1, a collaborative effort involving personnel distributed across ten institutions in two 
different countries, China and Germany, led to the publication of a report, authored by Xu 
et al., on the SUMOylation of the NS1 protein of the highly pathogenic avian influenza 
A/Duck/Hubei/L-1/2004 H5N1 viral strain (published online on 3 November 2010) [161]. 
According to that report, the authors initially identified Ubc9 as a host-cell protein capable 
of interacting with a truncated form of NS1 (ending at position 162) in a yeast two hybrid 
screening executed with the goal of identifying novel host cell protein interactors for NS1. 
The authors then demonstrated that the H5N1 NS1 is SUMOylated in vivo when over-
expressed by transfection, as were the NS1 proteins encoded by most viral strains tested, 
with the sole exception of the NS1 derived from the A/Sichuan/1/2009 H1N1 2009 pandemic 
strain. The authors also demonstrated that over-expression of the SUMO-deconjugating 
enzyme SENP1 abolished NS1 SUMOylation, and provided data indicative of NS1 
SUMOylation during infection. Subsequent analyses mapped the SUMOylation site in the 
H5N1 NS1 at residue K221, but indicated that residue K219 could provide an alternative 
SUMOylation site when K221 was mutated [161].  
One of the most important functions associated to NS1 during infection is its ability to 
neutralize the cellular type-I interferon (IFN) response. In the report by Xu et al., the authors 
compared the type I IFN-inhibiting activity of the wild-type (wt) NS1 with that of the non-
SUMOylatable mutant and found a slight decrease in the non-SUMOylatable mutant's 
ability to neutralize the IFN response.  Subsequent cycloheximide analyses indicated that 
the non-SUMOylatable NS1 appeared to have a substantial reduction in its stability, 
therefore accumulating to significantly lower levels in the cell. This property was then 
considered to be responsible for the non-SUMOylatable mutant's decreased ability to 
neutralize the type I IFN response. Finally, to study the potential effects of SUMOylation on 
viral growth, the authors developed a recombinant virus carrying a non-SUMOylatable NS1 
in which K219 and K221 were changed to glutamic acid to prevent introducing mutations in 
NS2, which is encoded by a spliced transcript of the NS gene segment. The resulting mutant 
virus grew to almost identical titers as the wt virus, but exhibited a 10 fold decrease in viral 
production at 8 hours post-infection [161].  
Recent data obtained by our group further supported the relevance of SUMOylation for 
NS1, although slight differences with the data presented in the paper by Xu et al. were 
observed. Such differences provide alternative mechanistic scenarios to explain the 
molecular effects of SUMOylation on NS1 function. First, our mapping analyses yielded 
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somewhat different data: According to our findings (Santos et al., manuscript in revision), 
the primary SUMOylation site in NS1 is not residue K221 but residue K219, which shows 
partial conservation among different viral strains. Our analyses have also mapped a 
secondary SUMOylation site in NS1, located in residue K70, a residue that is almost 
perfectly conserved among all influenza A viral strains. Thus, to abrogate NS1 
SUMOylation, it is necessary to simultaneously mutate both, K219 and K70. To this end we 
developed a double mutant form of NS1, hereafter referred to as NS1K70AK219A, in which 
both lysines were substituted by alanine. Second, protein stability analyses using 
cycloheximide also produced slightly different data: Despite numerous repeats, our 
experiments did not show differences between the stability of the non-SUMOylatable 
NS1K70AK219A mutant and that of wt NS1 (Santos et al., manuscript in revision). 
Therefore, our data  indicates that SUMOylation does not appear to regulate NS1's stability. 
Finally, viral replication assays demonstrated that NS1's ability to become SUMOylated 
exerts more dramatic effects on viral multiplication (as evidenced by the viral titers 
produced during infection) than those observed by Xu. et al. During the execution of these 
experiments, we decided to prevent introducing mutations affecting NS2 in the virus 
carrying the NS1K70AK219A mutant form of NS1 by mutating the splicing acceptor site 
located in NS1 and moving it, together with a full copy of the second exon for NS2, 
downstream from the stop codon for NS1. This strategy had been previously developed and 
successfully implemented by Varble et al. and offers the advantage of allowing the 
independent manipulation of NS1 and NS2 while still allowing NS2 to be produced as a 
splicing product of the primary transcript transcribed off the NS gene segment [162]. The NS 
gene segment generated in this way, hereafter referred to as NS1K70AK219A~NS2wt, 
produces a non-SUMOylatable NS1 and a wt NS2. To allow proper comparison of growth 
characteristics in the absence of other potential effects due to the alterations introduced in 
the NS gene segment, we also developed an equivalent NS gene segment coding for wt 
(SUMOylatable) NS1, hereafter referred to as NS1wt~NS2wt. The resulting recombinant 
viruses generated with those NS gene segments, produced by reverse genetics, exhibited 
striking differences in growth: The virus carrying the NS1wt~NS2wt gene segment 
produced viral titers that were more than two orders of magnitude (i.e. 100 fold) higher than 
the virus carrying the NS1K70AK219A~NS2wt gene segment, therefore supporting a very 
important biological role for the SUMOylation of NS1. 
To better understand the effects mediated by SUMOylation on NS1, in addition to 
producing the non-SUMOylatable form of NS1, we also developed an artificial SUMO ligase 
(ASL) specific for NS1 (hereafter referred to as NS1-ASL). This innovative tool allows NS1 
SUMOylation to be dramatically increased in the absence of any other noticeable change in 
the SUMOylation of any other protein within the cell (Pal et al., manuscript in preparation). 
Using this tool we have recently demonstrated that a ~4 fold increase in the fraction of 
SUMOylated NS1 produces a 25% decrease in NS1's ability to block type I IFN production, 
whereas blocking NS1 SUMOylation (by introducing the K70A and K219A mutations) 
produces a 60% decrease in NS1's ability to inhibit type I IFN production. This intriguing 
observation suggests that there is an intrinsic optimal balance in NS1's SUMOylation levels, 
and that whenever such balance is disrupted, whether by increasing or decreasing the 
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proportion of SUMOylated NS1 present in the cell, NS1's IFN blocking activity is 
diminished. A likely explanation for this model relates to SUMO's ability to modulate the 
protein interactions established by its targets. NS1 is known to interact with numerous viral 
and cellular proteins, potentially forming a large number of different protein complexes, 
each associated to specific roles mediated by NS1. More than one of such complexes may 
affect NS1's abililty to neutralize type I IFN production. For instance, a homo-multimeric 
NS1 complex might be ideal for coating the viral RNA, therefore preventing RIG-I 
activation, whereas a complex of NS1 and CPSF might be needed to down-regulate the 
production of mature cellular mRNAs, including those coding for type I IFNs. Then, it is 
possible that the levels of SUMOylated NS1 dictate the types of complexes formed by NS1 and 
their proportion, so that altering the levels of SUMOylated NS1 will affect NS1's function by 
altering the proportion and nature of the different complexes formed by NS1. Native gels 
performed with cell extracts derived from cells expressing either NS1wt or NS1K70AK219A, 
with and without co-expression of the NS1-ASL, have provided experimental support by this 
hypothetical model by demonstrating SUMOylation-dependent changes in the protein 
complexes formed by NS1 (Pal et al., manuscript in preparation).  
Altogether, our data indicates that the molecular effects mediated by SUMOylation on NS1 
are likely to be complex and multifactorial, and that a molecular characterization of the 
complexes formed by SUMOylated and non-SUMOylated NS1 will be needed to truly 
understand how SUMOylation affects NS1 function. Furthermore, our data also indicates 
that it will be necessary to explore in detail the effects of SUMOylation upon NS1 proteins 
derived from numerous viral strains, as it is likely that the differences observed between the 
data reported by Xu et al. and our own analyses may reflect strain-specific effects mediated 
by SUMOylation on NS1 function. Such differences may in turn reflect differences in the 
distribution of SUMOylation sites in NS1.   
4.6. A SUMO-dependent matrix: Relevance of the cellular SUMOylation system 
for the biological functions of the viral matrix protein M1 
An important addition to the history of the interactions established between the 
SUMOylation system and influenza virus was published online on 20 April 2011 by We et 
al. [163]. In their manuscript, Wu et al. reported a critical role for SUMO in viral assembly, 
mediated by the SUMOylation of the M1 protein. The study was initiated by experiments 
aimed at evaluating whether knocking down the cellular expression of Ubc9 by an RNAi 
approach affected influenza virus multiplication in Huh7 cells (a hepatoma cell line). 
Interestingly, cells exhibiting an almost complete knock-down of Ubc9 (achieved by 
transducing the cells with a lentivirus carrying an shRNA against Ubc9 followed by 
puromycin selection of the transduced cells) exhibited a decrease of two orders of 
magnitude in viral production when compared with cells transduced with a lentivirus 
lacking an Ubc9-specific shRNA. Subsequent analyses demonstrated that the changes in 
viral production were not mirrored by similar changes in viral protein synthesis. More 
surprisingly, vRNA accumulation within the Ubc9 knocked-down cells appeared increased, 
therefore suggesting a defect in viral release and a potential role for SUMOylation during 
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viral maturation and assembly. The authors then focused their attention on M1, an 
important player in viral assembly, and found it to be SUMOylated at position K242 [163].  
To determine the role of M1 SUMOylation during viral infection, the authors developed a 
recombinant A/WSN/1933 H1N1 virus carrying a non-SUMOylatable form of M1 containing 
a lysine to glutamic acid substitution at position K242, hereafter referred to as M1K242E. The 
lysine to glutamic acid substitution was chosen to prevent introducing any mutations on M2, 
the other protein encoded by the M gene segment. The mutant virus produced final viral titers 
two orders of magnitude lower than those produced by the wt virus. Interestingly, the cellular 
distribution of the NP protein appeared to be substantially altered in cells infected with the 
mutant virus, displaying a mostly nuclear localization even late during infection, a time when 
most of the NP signal is usually localized in the cytoplasm and in close proximity to the 
plasma membrane. However, according to the authors, the cellular localization of M1 was not 
affected. This suggested that M1 SUMOylation could potentially affect the nuclear export of 
vRNPs by enhancing their interaction with M1. A subsequent series of immunoprecipitation 
analyses showed that, in the presence of the non-SUMOylatable form of M1, the interactions 
between M1 and two proteins normally associated with vRNPs, PB2 and NP, were 
substantially decreased. This provided empirical support to the role of M1 SUMOylation in 
enhancing the interaction between M1 and vRNPs. Further support was provided by 
transmission electron microscopy data showing that, in cells infected with the mutant virus, a 
high number of empty virus-like particles and viral particles with abnormal morphology were 
produced, defects normally associated with a weak M1-vRNP interaction [163].  
Altogether, the report by Wu et al. presented a very compelling story demonstrating a role 
for M1 SUMOylation in enhancing the interaction between M1 and the vRNP. We have also 
observed the SUMOylation of M1 in our own studies, a fact that we reported in our paper 
published online on 3 March 2011, although we did not succeed in mapping its SUMOylation 
site. It will be interesting in the future to determine the specific protein interactions that are 
modulated by M1 SUMOylation, as M1 is known to establish multiple interactions, not only 
with other viral proteins but also with cellular proteins. A molecular characterization of such 
interactions may help define new druggable targets in cellular proteins.  
4.7. The future of the wrestling match: The potential relevance of the 
SUMOylation system for the development of innovative antiviral therapies 
In addition to the unquestionable role played by SUMOylation for the NS1 and M1 viral 
proteins, described in the sections above, data generated in our laboratory supports the idea 
that the interactions between the cellular SUMOylation system and influenza virus are even 
more complex than already indicated. This statement is supported by two main findings: 
First, in addition to NS1 and M1, our analyses have demonstrated that other viral proteins, 
namely PB1, NP, NEP [157], PB2, and PB1-F2 (Santos et al., manuscript in preparation) are 
also SUMOylated during infection . Second, analyses performed looking at the global profile 
of cellular SUMOylation at different points post-infection have demonstrated that influenza 
infection causes a global increase in cellular SUMOylation, characterized by the appearance 
of two new SUMOylated proteins of ~70 kD and 52 kD [157].   
 
Influenza A Virus Multiplication and the Cellular SUMOylation System 29 
Out of the new viral proteins identified as SUMO targets, our recent studies have already 
indicated that SUMOylation plays an important regulatory role for the viral polymerase 
subunit PB1, and ongoing analyses suggest that the same might be true for NEP 
(unpublished observations). This implies that, besides helping regulate NS1's IFN-
neutralizing activity and M1's role in viral morphogenesis (two well established effects of 
SUMOylation on influenza infections as discussed above), the cellular SUMOylation system 
may also regulate PB1's role in viral transcription and replication, and NEP's role in the 
nuclear export of vRNPs. Our studies have demonstrated the existence of an optimal 
proportion of SUMOylated and non-SUMOylated NS1 that maximizes its IFN-inhibitory 
activity. It is likely that a similar optimal proportion between the SUMOylated and non-
SUMOylated forms may also exist for all the other viral proteins targeted by the cellular 
SUMOylation system. This possibility emphasizes one important feature of the 
SUMOylation system that makes it an especially attractive target for the development of 
new antiviral therapies: Alterations affecting the activity of the SUMOylation system, 
whether increasing it or decreasing it, will affect the proportions of SUMOylated and non-
SUMOylated forms of not just one but several viral proteins. This will likely result in 
pronounced alterations in the proportions of the various protein complexes made by each 
viral protein during infection, which will in turn decrease viral multiplication by affecting 
multiple stages of influenza's life cycle. Therefore, the SUMOylation system constitutes one 
cellular target whose disruption would likely have multiple damaging effects on viral 
multiplication without having immediate deadly consequences for the cell. Proof of 
principle for this idea has already been provided by two studies that have demonstrated 
substantial decreases in viral multiplication when the SUMO conjugating enzyme is 
targeted by an RNAi approach [92, 94]. From this perspective, it is conceivable that the 
ongoing NIH-sponsored efforts by other laboratories to develop drug-like specific inhibitors 
of the cellular SUMOylation system may, in the long run, yield a new generation of anti-
influenza drugs, some of which may prove useful against other viral diseases as well.  
Viruses have developed numerous strategies to gain control over the cellular environment 
of the host as a way to maximize their own fitness. Many of the cellular systems whose 
activity is increased during viral infections are purposely increased to facilitate viral 
multiplication. However, other cellular systems are increased as a way to neutralize viral 
infection, as exemplified by the large number of cellular genes that are turned on by the IFN 
response. Our analyses have demonstrated that influenza A infections produce a dramatic 
increase in the activity of the cellular SUMOylation system [157]. This has been 
demonstrated for a large number of viral strains and cell lines, and therefore is likely to 
represent a general feature of influenza A infections. We have also proven that the global 
increase in cellular SUMOylation requires the presence of a transcriptionally active virus, as 
UV inactivated viruses are unable to trigger it [157]. Additional analyses have also indicated 
that IFN stimulation is neither sufficient nor required to trigger the increase, as direct 
addition of recombinant IFN-β to uninfected cells does not result in a global increase in 
cellular SUMOylation, and cells lacking the ability to produce IFN (such as Vero cells) also 
exhibit the increase upon viral infection [157]. Although these findings strongly suggest that 
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the global increase in cellular SUMOylation is triggered by a virus-dependent mechanism, it 
is uncertain whether the increase itself corresponds to a viral strategy to enhance viral 
growth, or a cellular attempt at neutralizing viral infection. It appears tempting to choose 
the first scenario, particularly because of the already demonstrated relevance of 
SUMOylation for a number of viral proteins [161, 163]  and the demonstrated decrease in 
viral multiplication observed upon targeting Ubc9 by RNAi [92, 94]. However, at this point 
we consider that it is still possible that some of the SUMOylation events that are induced 
during infection may have antiviral effects. Our ongoing studies have already identified the 
minimal set of viral components required to trigger the global increase in cellular 
SUMOylation described above (Chacon, Santos, et al., manuscript in preparation), and 
recent data have revealed an unanticipated twist in the story. We are confident that further 
characterization of the molecular mechanisms involved in the global increase in cellular 
SUMOylation by influenza virus will lead to a new paradigm for the interactions established 
between viruses and the SUMO system. 
5. Conclusions 
IAV remains one of the most damaging viruses for humans. Our knowledge of the molecular 
mechanisms involved in viral transcription and replication has increased dramatically, and with 
it, we have also gained new insights into how the host cell is affected by the virus to enhance 
viral functions, and how cellular functions affect viral replication. However, numerous 
questions remain, particularly in areas related to the dynamic interplay that takes place between 
the numerous cellular systems affected by the virus and the viral proteins that trigger those 
effects. A better understanding of the interplay established between the virus and its host cell is 
likely to result in the development of new therapeutic agents for the treatment and prevention 
of complicated influenza infections, which is, in our opinion, one of the most urgent medical 
needs of our time due to the impending threat of new pandemics.  Research started by our 
group about 7 years ago has began to unveil some of the multiple roles that the cellular 
SUMOylation system plays during the life cycle of IAV. The variety and significance of those 
roles for viral fitness identifies the SUMO system as one of the most promising targets for the 
development of novel broad-spectrum, host-cell targeted, anti-influenza therapies, which could 
also be applicable to the treatment of other acute viral diseases.   
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